KDM1A and breast cancer: To this end, we treated ΜCF-7 and MDA-MB-468 breast cancer cells with a highly specific LSD1 inhibitor, GSK-LSD1 [42] or vehicle (phosphate-buffered saline, PBS) for 7 days and, also, exposed them to increasing doses of doxorubicin (0–5 μM), a drug commonly given to breast cancer patients, for the last 2 days.